Patents Assigned to DENALI THERAPEUTICS, INC.
  • Publication number: 20250145729
    Abstract: The present disclosure includes engineering methods and polypeptide libraries that are useful for introducing non-native binding sites into polypeptides. Also provided herein are polypeptides that bind to a CD98hc or transferrin receptor (TfR) protein, methods of generating such polypeptides, and methods of using the polypeptides to target a composition across the blood-brain barrier or to a CD98hc-expressing or TfR-expressing cell.
    Type: Application
    Filed: December 16, 2022
    Publication date: May 8, 2025
    Applicant: DENALI THERAPEUTICS INC.
    Inventors: Padma Akkapeddi, Gerald Maxwell Cherf, Kylie S. Chew, Mark S. Dennis, Zhenyu Gu, Mihalis S. Kariolis, Hai L. Tran, Robert C. Wells, Joy Yu Zuchero
  • Publication number: 20250136963
    Abstract: Provided herein are proteins, which are capable of being transported across the blood-brain barrier (BBB) and comprise an alpha-L-iduronidase (IDUA) enzyme-Fc fusion polypeptide. Certain embodiments also provide methods of using such proteins to treat MPS I.
    Type: Application
    Filed: December 16, 2022
    Publication date: May 1, 2025
    Applicant: DENALI THERAPEUTICS INC.
    Inventors: Gowrisudha ADUSUMILLI, Oliver Brayer DAVIS, Mihalis S. KARIOLIS, Cathal S. MAHON, Shrishti TYAGI, Kensuke YAMANOKUCHI
  • Patent number: 12240902
    Abstract: In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody decreases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody enhances TREM2 activity.
    Type: Grant
    Filed: August 16, 2021
    Date of Patent: March 4, 2025
    Assignee: Denali Therapeutics Inc.
    Inventors: Mark S. Dennis, Sherie Duncan, Kathleen Lisaingo, Kathryn M. Monroe, Joshua I. Park, Rachel Prorok, Ju Shi, Ankita Srivastava, Bettina Van Lengerich, Riley Walsh
  • Publication number: 20250018015
    Abstract: Certain embodiments provide a method of providing added peripheral IDS activity to a subject with Hunter syndrome, comprising administering to the subject a therapeutically effective dose of a pharmaceutical composition comprising a protein comprising an IDS amino acid sequence and a TfR binding domain. The added peripheral IDS activity can be measured by comparing levels of keratan sulfate (KS) in the subject after administration of the pharmaceutical composition relative to a baseline level. Certain embodiments also provide methods of providing a clinical benefit to a subject with Hunter syndrome and improving treatment in a patient having non-neuronopathic Hunter syndrome, as well as methods and treatment regimens for resolving infusion related reactions (IRRs).
    Type: Application
    Filed: July 22, 2022
    Publication date: January 16, 2025
    Applicant: DENALI THERAPEUTICS INC.
    Inventors: Annie ARGUELLO, Akhil BHALLA, Jeffrey Mark HARRIS, Matthew D. TROYER
  • Publication number: 20250011338
    Abstract: The present disclosure relates generally to compounds and compositions, intermediates, processes for their preparation, and their use as kinase inhibitors.
    Type: Application
    Filed: September 18, 2024
    Publication date: January 9, 2025
    Applicant: Denali Therapeutics Inc.
    Inventors: Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Cinzia Maria Francini, Christopher R.H. Hale, Cheng Hu, Colin Philip Leslie, Maksim Osipov, Elena Serra, Zachary K. Sweeney, Arun Thottumkara
  • Patent number: 12180211
    Abstract: The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.
    Type: Grant
    Filed: June 17, 2021
    Date of Patent: December 31, 2024
    Assignee: DENALI THERAPEUTICS INC.
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Cheng Hu, Maksim Osipov, Zachary K. Sweeney, Javier de Vicente Fidalgo, Arun Thottumkara
  • Publication number: 20240420490
    Abstract: Methods and systems described herein may allow for the classification of microglial morphology at single cell resolution. Microglial cell states may be determined, and a biological sample from which the microglial cells are obtained may be classified based on the microglial cell states. Classifying microglial cells may involving segmenting microglia cells into soma and processes in immunofluorescence microscopy images. Additionally, a feature bank may be generated. Values of the features in the feature bank may be measured for an image. Cells may be clustered using the values of the features in the feature bank. The cells in a cluster may be compared to a reference cell with a known state and having known morphological properties. The cluster in the cell may then be assigned the same state as a reference cell. The amount of cells having the state may then be used to determine properties of the biological sample.
    Type: Application
    Filed: October 19, 2022
    Publication date: December 19, 2024
    Applicant: Denali Therapeutics Inc.
    Inventors: Meredith Calvert, David Joy
  • Patent number: 12162948
    Abstract: Provided herein are polypeptides that bind to a transferrin receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a transferrin receptor-expressing cell.
    Type: Grant
    Filed: April 23, 2024
    Date of Patent: December 10, 2024
    Assignee: Denali Therapeutics Inc.
    Inventors: Xiaocheng Chen, Mark S. Dennis, Mihalis Kariolis, Adam P. Silverman, Ankita Srivastava, Ryan J. Watts, Robert C. Wells, Joy Yu Zuchero
  • Publication number: 20240391933
    Abstract: Described herein are crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide, the process of preparing the forms, and pharmaceutical compositions methods of use thereof.
    Type: Application
    Filed: April 25, 2024
    Publication date: November 28, 2024
    Applicant: Denali Therapeutics Inc.
    Inventor: Anantha Sudhakar
  • Patent number: 12139478
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, and methods of making and using thereof.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: November 12, 2024
    Assignee: Denali Therapeutics Inc.
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Katrina W. Lexa, Maksim Osipov, Zachary K. Sweeney
  • Patent number: 12129263
    Abstract: The present disclosure relates generally to compounds and compositions, intermediates, processes for their preparation, and their use as kinase inhibitors.
    Type: Grant
    Filed: October 26, 2021
    Date of Patent: October 29, 2024
    Assignee: DENALI THERAPEUTICS INC.
    Inventors: Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Cinzia Maria Francini, Christopher R. H. Hale, Cheng Hu, Colin Philip Leslie, Maksim Osipov, Elena Serra, Zachary K. Sweeney, Arun Thottumkara
  • Publication number: 20240317776
    Abstract: Described herein are solid forms of 4-(3,3-difluoro-2,2-dimethyl-propanoyl)-3,5-dihydro-2H-pyrido[3,4-f][1,4]oxazepine-9-carbonitrile, the process of preparing the forms, pharmaceutical compositions comprising same, and methods of use thereof.
    Type: Application
    Filed: February 20, 2024
    Publication date: September 26, 2024
    Applicant: Denali Therapeutics Inc.
    Inventors: Javier de Vicente Fidalgo, Brian M. Fox, Christopher R.H. Hale
  • Patent number: 12091392
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, and methods of making and using thereof.
    Type: Grant
    Filed: February 12, 2020
    Date of Patent: September 17, 2024
    Assignee: Denali Therapeutics Inc.
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Jianwen A. Feng, Maksim Osipov, Arun Thottumkara
  • Publication number: 20240271326
    Abstract: Provided herein are polypeptides that bind to a transferrin receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a transferrin receptor-expressing cell.
    Type: Application
    Filed: February 7, 2024
    Publication date: August 15, 2024
    Applicant: Denali Therapeutics Inc.
    Inventors: Xiaocheng Chen, Mark S. Dennis, Mihalis Kariolis, Adam P. Silverman, Ankita Srivastava, Robert C. Wells, Joy Yu Zuchero, Ryan J. Watts
  • Publication number: 20240271327
    Abstract: Provided herein are polypeptides that bind to a transferrin receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a transferrin receptor-expressing cell.
    Type: Application
    Filed: April 23, 2024
    Publication date: August 15, 2024
    Applicant: Denali Therapeutics Inc.
    Inventors: Xiaocheng Chen, Mark S. Dennis, Mihalis Kariolis, Adam P. Silverman, Ankita Srivastava, Ryan J. Watts, Robert C. Wells, Joy Yu Zuchero
  • Patent number: 11999750
    Abstract: Described herein are crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide, the process of preparing the forms, and pharmaceutical compositions methods of use thereof.
    Type: Grant
    Filed: January 11, 2023
    Date of Patent: June 4, 2024
    Assignee: DENALI THERAPEUTICS INC.
    Inventor: Anantha Sudhakar
  • Publication number: 20240148866
    Abstract: Certain embodiments provide a fusion protein comprising an iduronate 2-sulfatase (IDS) amino acid sequence, an IDS variant amino acid sequence, or a catalytically active fragment thereof; and an anti-transferrin receptor (TfR) antibody as described herein, as well as methods of use thereof.
    Type: Application
    Filed: February 11, 2022
    Publication date: May 9, 2024
    Applicant: DENALI THERAPEUTICS INC.
    Inventors: Annie ARGUELLO, Tina GIESE, Gunasekaran KANNAN, Mihalis S. KARIOLIS, Cathal S. MAHON, Junhua WANG
  • Publication number: 20240150736
    Abstract: Provided herein are proteins, which are capable of being transported across the blood-brain barrier (BBB) and comprise sulfoglucosamine sulfohydrolase (SGSH) enzyme-Fc fusion polypeptides. Certain embodiments also provide methods of using such proteins to treat Sanfilippo syndrome A.
    Type: Application
    Filed: January 12, 2024
    Publication date: May 9, 2024
    Applicant: DENALI THERAPEUTICS INC.
    Inventors: Tina GIESE, Gunasekaran KANNAN, Mihalis S. KARIOLIS, Cathal S. MAHON
  • Publication number: 20240150376
    Abstract: The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.
    Type: Application
    Filed: August 10, 2023
    Publication date: May 9, 2024
    Applicant: Denali Therapeutics Inc.
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Colin Phillip Leslie, Joseph P. Lyssikatos, Alfonso Pozzan, Zachary K. Sweeney, Javier de Vicente Fidalgo
  • Publication number: 20240141058
    Abstract: Provided herein are polypeptides that bind to a transferrin receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a transferrin receptor-expressing cell.
    Type: Application
    Filed: January 9, 2024
    Publication date: May 2, 2024
    Applicant: Denali Therapeutics Inc.
    Inventors: Xiaocheng Chen, Mark S. Dennis, Mihalis Kariolis, Adam P. Silverman, Ankita Srivastava, Ryan J. Watts, Robert C. Wells, Joy Yu Zuchero